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PERSPECTIVE
Expanding Precompetitive 
Multisector Collaborations to 
Advance Drug Development 
and Pharmacogenomics
Sook Wah Yee1, Thao P. Do2, Shiew-Mei Huang3, Ronald M. Krauss4, 
Hiroyuki Kusuhara5, Yuichi Sugiyama6, Jashvant D. Unadkat7 and 
Kathleen M. Giacomini1,*
Drug development requires a myriad of preclinical and clinical 
studies to understand the pharmacokinetics, efficacy, and 
toxicity of new drugs in patients. To inform these studies, a 
common base of knowledge is required. In this commentary, we 
provide an overview of several multidisciplinary consortia that 
support precompetitive drug development and pharmacogenomics 
research. The goal of this commentary is to stimulate awareness 
of consortia that advance knowledge in clinical pharmacology.
This commentary provides many examples 
of consortia from multiple sectors that work 
together to conduct research in drug develop­
ment and pharmacogenomics. Examples are 
selected to demonstrate differences in funding 
mechanisms, membership, and collaborative 
goals and needs. Many consortia are funded 
by research grants from the government (e.g., 
the National Institute of Health (NIH)), pub­
lic–private partnerships (e.g., the European 
Innovative Medicines Initiative (IMI) (https ://
www.imi.europa.eu/), Horizon 2020 (https ://
ec.europa.eu/progr ammes/ horiz on202 0/en)), 
or commercial entities, (e.g., pharmaceutical 
and biotechnology industry). However, there 
are examples of consortia, which are formed 
voluntarily by scientists from multiple sectors, 
that have no source of funding. Table 1 and 
the associated Supplementary Information 
provide an extensive list of consortia in drug de­
velopment and pharmacogenomics. For each 
consortium, the membership, funding source, 
and link to the relevant website are provided.
CONSORTIA FOCUSING ON DRUG 
DEVELOPMENT
Table 1 and the associated Supplementary 
Information provide a list of active con­
sortia focused on drug development, in­
cluding drug discovery. Four consortia 
focused on scientific issues that are rele­
vant to drug development, and in partic­
ular, drug–drug interactions are described 
in more detail below.
The International Transporter Consor­
tium (ITC) was founded without financial 
support in 2007 by key scientists with ex­
pertise in drug metabolism, transport, and 
pharmacokinetics from multiple sectors (ac­
ademia, industry, and the US Food and Drug 
Administration (FDA)). ITC investigators 
from the United States, Europe, and Asia are 
interested in the role of drug transporters in 
drug safety and efficacy (https ://www.itc­
trans porter.org/). The first workshop held in 
2008 was a collaborative effort with the FDA 
that resulted in a white paper on membrane 
transporters in drug development1 that ex­
emplified the aims of the FDA’s Critical Path 
Initiative (https ://www.fda.gov/scien ce­re­
sea rch/scien ce­and­resea rch­speci al­topic s/
criti cal­path­initi ative ). Since 2008, a total 
of three workshops and two joint workshops 
on drug transporters in absorption, distribu­
tion, metabolism, and elimination have pro­
vided critical updates and recommendations 
that were incorporated into several white 
papers, each addressing important areas in 
drug development, including drug–drug 
interactions (DDIs), transporter polymor­
phisms, emerging transporters of clinical 
importance, in vitro methods for transporter 
evaluation, recommendations related to 
clinical study design, and potential clinical 
probes and endogenous biomarkers, among 
others.2,3 Although great advances have 
been made in our understanding of factors 
affecting transporter function and clinical 
relevance, challenges remain, and the knowl­
edge gaps must continue to be addressed via 
collaborative efforts, such as the ITC. The 
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Table 1 A list of consortia or networks consisting of members from academia, industry, and government working together to 
meet goals related to drug discovery and development or pharmacogenomics
Consortium name (acronym) Goal Members Financial support
Drug discovery and development
Academic Drug Discovery 
Consortium (AD2C)
To build a collaborative network among the growing number of 
university-led drug discovery centers and programs.
Academia, Industry Industry
Accelerating Therapeutics 
for Opportunities in 
Medicine (ATOM)
The mission is to transform drug discovery by accelerating 
methods and tools used in drug discovery and development.
Academia, Industry Public–private 
partnership
Biomarker Consortium To discover and validate endogenous substrates for 
transporters involved in drug absorption and elimination.
Academia, Industry Industry
Drug-Induced Liver Injury 
Network (DILIN)
To collect and analyze cases of severe liver injury caused by 
prescription drugs, over-the-counter drugs, and alternative 
medicines, such as herbal products and supplements.
Academia NIH
Kinetics for Drug Discovery 
(K4DD) Consortium
To enable the adoption of drug-target binding kinetics 
analysis in the drug discovery decision-making process, and 
thereby contribute to the development of a new generation of 
improved medicinal products.
Academia, Industry Industry-driven 
public-private 
partnership
Illuminating the Druggable 
Genome (IDG)
IDG Consortium is a U54 program funded by the NIH Common 
Fund with the goal of shedding light on understudied targets.
Academia NIH
Innovation and Quality (IQ) 
International Consortium
Organization of pharmaceutical and biotechnology companies 
with the mission of advancing science and technology to 
augment the capability of member companies to develop 
transformational solutions that benefit patients, regulators, 
and the broader R&D community.
Industry Industry
International Transporter 
Consortium (ITC)
To advance our understanding of transporter biology in drug 
development with the goal of improving human health.
Academia, Industry, 
Government
None
PET-IVIVE Consortium 
(2015-2019)
Predicting the role of hepatic transporters in pharmacokinetic 
(PK) and tissue concentrations via in vitro assays and drug PK 
and tissue concentrations in humans quantified by Positron 
Emission Tomography (PET).
Academia, Industry Industry
Structural Genomics 
Consortium (SGC)
The SGC catalyses research in new areas of human biology 
and drug discovery by focusing explicitly on less well-studied 
areas of the human genome.
Academia, Industry Public–private 
partnership
University of Washington 
Research Affiliate Program 
on Transporters (UWRAPT)
Quantifying absolute expression of transporters and 
enzyme in various tissues and cells to predict interindividual 
variability in drug clearance and tissue concentrations.
Academia, Industry Industry
Pharmacogenomics
Clinical Pharmacogenetics 
Implementation 
Consortium (CPIC)
Facilitating the use of pharmacogenetic tests for patient care. Academia, Industry NIH
French National Network of 
Pharmacogenetics (RNPGx)
Issue recommendations based on level of evidence whether 
pharmacogenetic tests are needed for patient care.
Academia, Hospital, 
Private laboratory
None
Industry 
Pharmacogenomics 
Working Group (I-PWG)
To improve patient care through integration of 
pharmacogenomics in drug development.
Industry Industry
PharmacoGenetics and 
PharmacoGenomics 
Research (A network in The 
European Federation For 
Pharmaceutical Sciences, 
EUFEPS)
The Network provides a platform for experts for gathering 
and disseminating knowledge, determining PGx-strategies; 
for collaboration between academic institutions and industry; 
for mechanisms of setup and exchange of databases; 
and for gathering and promotion of knowledge about 
pharmacogenetics and genomics in Europe.
Academic, Industry Academic, Industry
Pharmacogene Variation 
Consortium (PharmVar)
A central repository for pharmacogene variation that focuses 
on haplotype structure and allelic variation.
Academia, Industry NIH
Pharmacogenomics 
Knowledgebase Resource 
(PharmGKB)
Collects, curates, and disseminates knowledge about the 
impact of human genetic variation on drug responses through 
the various activities.
No membership NIH
Pharmacogenomics 
Research Network (PGRN)
To catalyze and lead research in precision medicine for the 
discovery and translation of genomic variation influencing 
therapeutic and adverse drug effects.
Academia, Industry, 
Government
NIH
 (Continued)
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fourth workshop will occur on March 8–9, 
2021, with input from ITC members.
University of Washington Research 
Affiliate Program on Transporters 
(UWRAPT) was established by Dr. Jashvant 
Unadkat at the University of Washington in 
2012 through support from pharmaceutical 
companies (https ://sop.washi ngton.edu/
uwrap t/). The goal of UWRAPT is to better 
understand and predict interindividual vari­
ability in pharmacokinetics and pharmaco­
dynamics of drugs. Specifically, UWRAPT 
aims to predict transport­mediated drug dis­
position including tissue drug concentrations 
using the relative expression factor (REF), 
which relies on quantification of transporter 
proteins in various human/animal tissues and 
cells using quantitative targeted proteomics 
(liquid chromatography–tandem mass 
spectrometry). Key findings of UWRAPT 
research fall into two main categories: (i) 
quantification of transporters and enzymes in 
various human and animal tissues,4 including 
those obtained from diseased (e.g., cirrhosis)5 
and pediatric populations;6 and (ii) the use 
of these data for in vitro to in vivo extrapo­
lation of drug disposition (including tissue 
Consortium name (acronym) Goal Members Financial support
Pharmacogenomics 
Working Group (within the 
Global Genomic Medicine 
Collaborative (G2MC))
The Pharmacogenomics (PGx) Working Group works on 
genomic research and database projects to address severe 
drug-induced adverse events.
Academic, Industry Previously was 
supported by 
NIH and US 
NAM, currently 
independent not-
for-profit charitable 
organization
Southeast Asian 
Pharmacogenomics 
Research Network 
(SEAPharm)
To enable and strengthen pharmacogenomics research 
among the various pharmacogenomics communities 
within Southeast Asia, with the ultimate goal to support 
pharmacogenomics implementation in the region.
Academia Public, Industry
Ubiquitous 
Pharmacogenomics 
(U-PGX)
To make effective treatment optimization accessible to every 
European citizen.
Clinicians, Academia 
researchers
European 
Commission
UK Pharmacogenetics 
and Stratified Medicine 
Network (UKPSM)
To develop collaborative partnerships and to synergize 
research into stratified/personalized/precision medicine 
across the UK, and internationally, to support its adoption 
into the clinic.
Academia, Industry, 
Government
European 
Commission, 
UK Government, 
Meetings
Pharmacogenomics (focusing on a specific disease, drug class, or adverse drug event)
African American 
Cardiovascular 
Pharmacogenomics 
Consortium (ACCOUNT)
To ensure that all people, including African Americans, 
benefit fully from precision medicine.
Clinicians, academia 
researchers, 
community leaders, 
and patients
NIH
Canadian 
Pharmacogenomics 
Network for Drug Safety 
(CPNDS)
To solve drug safety problems by developing genetic tests 
that predict which patients are at risk of serious adverse drug 
reactions.
Academia, Industry Industry
Epilepsy 
Pharmacogenomics 
Consortium (EPIPGX)
EPIPGX is a unique pharmacogenomics project which 
brings together renowned scientists from various academic 
institutions and SMEs throughout Europe.
Academia, small to 
mid-size enterprise
None
Genetics of Osteosarcoma 
(GO-consortium)
Understanding and optimizing osteosarcoma treatment 
through genetics.
Academia Public
Metformin Genetics 
(MetGen Plus)
Diabetes studies that have genetic data and metformin and 
other antidiabetes drug treatment outcome measures.
Academia None
Pharmacogenomics in 
Childhood Asthma (PICA)
Bring together asthma studies that have genetic data and 
treatment outcome measures.
Academia None
Prediction ADR Consortium 
(Prediction-ADR)
Discover the genetic factors predisposing patients to adverse 
drug reactions (ADRs) from cardiovascular disease (CVD) 
drugs.
Academia European 
Community
The International Serious 
Adverse Events Consortium 
(ISAEC)
To identify DNA-variants useful in understanding the risk of 
drug-related serious adverse events (SAEs).
Academia, Industry, 
Government
Non profit
The Pharmacogenomics 
of Clozapine-Induced 
Myocarditis (PROCLAIM) 
Consortium
To uncover genomic markers that could be used preemptively 
by clinicians to identify those patients at highest risk 
for myocarditis from clozapine therapy and identify the 
mechanism by which clozapine induces myocardial 
inflammation and damage.
Academia Public
The hyperlink and references published by the consortia are listed in Supplementary Information. IVIVE, in vitro to in vivo extrapolation; NIH, National Institutes of 
Health; SMEs, small and medium-sized enterprises; US NAM, US National Academy of Medicine.
Table 1 (Continued)
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concentrations) mediated by transporters to 
predict drug disposition and tissue concentra­
tions, verified through imaging modalities.7 
See Supplementary Information for a list of 
publications from UWRAPT.
The Biomarker Consortium was founded 
recently in Japan by Drs Hiroyuki Kusuhara 
and Yuichi Sugiyama through support from 
industry. Many challenges remain in the 
prediction of transporter­mediated DDIs. 
These include induction and inhibition of 
transporters, as well as the effects of genetic 
polymorphisms in modulating DDIs. The 
goals of this consortium are to advance the 
characterization of endogenous substrates 
to provide compelling evidence that endog­
enous compounds are surrogate probes to 
quantitatively predict transporter­mediated 
DDIs and to establish physiologically­based 
pharmacokinetic models for predicting the 
effects of investigational compounds on en­
dogenous compounds. To achieve these goals, 
this project will provide evidence at three lev­
els: (i) in vitro data, (ii) animal data, and (iii) 
clinical data to increase the robustness of the 
physiologically­based pharmacokinetic mod­
els. Finally, the project will disclose the data 
to support the rationale for use of the endog­
enous probes in a publicly accessible database 
and in published manuscripts. Our most 
recent finding using coproporphyrin I as an 
endogenous biomarker will serve as a model 
for this consortium8 (Figure S1).
The Innovation & Quality (IQ) Consor­
tium is a dynamic and technically focused 
organization that impacts many areas of 
pharmaceutical development and regula­
tion. Membership is only opened to phar­
maceutical industry. IQ supports many 
leadership groups and working groups fo­
cusing on issues in pharmaceutical science 
including  the Translational and ADME 
Sciences Leadership Group, which focuses 
on studies related to drug  absorption, 
distribution, metabolism, and elimination, 
the Clinical Pharmacology Leadership 
Group, and others (https ://iqcon sorti 
um.org/about/ ).
Other consortia and networks relevant 
to drug discovery and development that are 
funded by NIH or public–private fundings 
include the Accelerating Therapeutics for 
Opportunities in Medicine (ATOM) consor­
tium, Drug­Induced Liver Injury Network 
(DILIN), Kinetics for Drug Discovery 
(K4DD) consortium, Illuminating the 
Druggable Genome (IDG), and Structural 
Genomics Consortium (SGC) (see Table 1, 
Supplementary Information).
CONSORTIA FOCUSING ON 
PHARMACOGENOMICS
Pharmacogenomics research is focused on 
understanding how an individual’s genes 
affect his or her response to medicines. 
Many of the networks or consortia that 
Figure 1 Illustration of multidisciplinary consortia that support precompetitive drug development and pharmacogenomics research.
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focus on pharmacogenomics research are 
founded in the United States or Europe 
but include researchers around the world 
(Table 1, Figure 1, and Supplementary 
Information). Furthermore, many phar­
macogenomics consortia study multi­
ple ethnic groups and disease­related 
populations. Below, we describe the 
Pharmacogenomics Research Network 
(PGRN) as an example of a broad­based 
pharmacogenomics research consortium, 
followed by a brief description of dis­
ease­specific or drug­specific pharmacog­
enomics research consortia.
The PGRN is an NIH­funded program 
whose mission is to catalyze and lead research 
in precision medicine for the discovery and 
translation of genomic variation influencing 
therapeutic and adverse drug effects. From 
2000 to 2015, a total of 16 pharmacogenom­
ics research groups, 7 network resources, and 
a Pharmacogenomics Knowledge Base have 
been supported by various NIH Institutes, 
led by the National Institute of General 
Medical Sciences. Since 2015, the PGRN 
has included three specialized centers (P50 
grants) and six resources (R24 grants) (https 
://www.pgrn.org/resea rch­pages.html).9 
In 2015, the PGRN membership structure 
was opened, and there are currently over 600 
members globally who are active in pharma­
cogenomics research, teaching, and clinical 
work. Members avail themselves of activities 
and resources coordinated by the PGRN 
Hub, including annual scientific meetings, a 
website rich in pharmacogenomics research 
tools and news (www.pgrn.org), social 
media posts, monthly Research in Progress 
Seminars, and quarterly member­wide calls. 
The major scientific accomplishments of 
PGRN­funded researchers include discov­
ery of genetic polymorphisms in genes that 
are critical for disposition of and response 
to many drugs, including those used to treat 
cancer and cardiovascular, respiratory, neu­
ropsychiatric, and rheumatologic diseases. 
Additional accomplishments include appli­
cation of genome­wide association methods 
to pharmacogenomics (https ://www.pgrn.
org/riken­publi catio ns.html), functional 
genomics studies of common and rare vari­
ants, development and utilization of induced 
pluripotent stem cells, and clinical imple­
mentation and standardization of pharma­
cogenomics testing (see Data S1, reading 
lists to learn more about PGRN).
Future directions
Financial support from NIH for the 
PGRN will end on June 30, 2020. PGRN 
is actively exploring various partnerships 
and mechanisms within the United States 
and globally to foster its continued leader­
ship role in pharmacogenomics research.
In addition to the PGRN, there are at least 
20 pharmacogenomics consortia where re­
searchers from around the world share data 
and knowledge to answer questions in phar­
macogenomics. These consortia may focus 
on particular drug classes, diseases, or ad­
verse drug events (Table 1, Supplementary 
Information). Drug­specific  pharmacog­
enomics consortia are formed (see https 
://www.pgrn.org) to pool and expand 
samples for increased power in pharma­
cogenomics research and to bring scientists 
and clinicians together to participate in 
study design, sample collection, and data 
analysis and interpretation. An example 
of a drug­specific consortium is MetGen 
Plus (formerly MetGen, see https ://www.
pgrn.org/metgen.html). This consortium 
originally began with a focus on identify­
ing pharmacogenomic  factors that associate 
with response to metformin, which is first­
line therapy for type 2 diabetes. Motivated 
by common interest, the original goal of the 
consortium was to replicate phenotypic and 
genetic findings relating to metformin re­
sponse through collaboration.10 This goal 
expanded to include other antidiabetic drugs. 
Examples of disease­focused and adverse 
drug reaction­focused pharmacogenomics 
research consortia are the African American 
Cardiovascular Pharmacogenomics 
Consortium (ACCOUNT), Genetics of 
Osteosarcoma (GO­Consortium), The 
Inter­ national Serious Adverse Events 
Consortium (ISAEC), and the Prediction 
ADR Consortium (Prediction­ADR). In ad­
dition, there are many other consortia, which 
were established previously, but have sunset­
ted due to completion of the project or lack 
of funding (e.g., see https ://www.pgrn.org/
riken­proje cts.html).
CONCLUSIONS
Diverse consortia exemplified in this per­
spective have greatly enhanced precompet­
itive research in drug development sciences 
and pharmacogenomics. Disease­specific 
scientific consortia have facilitated and 
empowered large genome­wide association 
studies of human disease. Increasingly, 
drug­specific pharmacogenomics con­
sortia are enabling genomewide stud­
ies of  pharmacogenomics phenotypes 
(Table 1). It is envisioned that such con­
sortia will increase in number as only a 
fraction of approved drugs have been stud­
ied using genomewide approaches. 
Similarly, multisector consortia such as 
the ITC, the Biomarker Consortium, and 
UWRAPT have enabled precompetitive 
research by providing much­needed ex­
pertise and knowledge that informs drug 
development. Though some consortia end 
naturally when their purpose is fulfilled, 
sustaining consortia is frequently challeng­
ing, often because of funding issues. Most 
consortia are formed by motivated scien­
tists, often from academia, with industry 
partners. A by­product of many of these 
consortia is that they support global col­
laborations and scientific exchange in drug 
development and  pharmacogenomics. In 
the future, consortia focused on pharma­
cogenomics, biomarkers, special popu­
lations, and modeling and simulation of 
new drugs and therapies, as well as many 
older drugs, will be formed to advance pre­
cision medicine. Clinical pharmacologists 
should continue to support these scientific 
consortia through membership, funding, 
and active participation.
SUPPORTING INFORMATION
Supplementary information accompanies 
this paper on the Clinical Pharmacology & 
Therapeutics website (www.cpt-journal.com).
Figure S1. The newly established biomarker 
consortium to discovery and validate endog-
enous substrates for transporters involved in 
drug absorption and elimination. Three main 
approaches are illustrated in this figure.
Supplementary Reading List
ACKNOWLEDGMENTS
We are grateful to Wooin Lee and Takashi 
Yoshikado for providing the flowchart in Figure S1.
FUNDING
We would like to acknowledge support 
from GM115370 (K.M.G., S.W.Y., T.P.D.), 
GM115318 (R.M.K.), and UWRAPT (J.D.U.) 
funded by various pharmaceutical companies.
CONFLICT OF INTEREST
The authors declared no competing interests 
for this work. As an Associate Editor for Clinical 
Pharmacology & Therapeutics, Kathleen M. 
Giacomini was not involved in the review or 
decision process for this paper.
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 107 NUMBER 1 | JANUARY 2020 101
PERSPECTIVES
DISCLAIMER
The contents of this article reflect the 
views of the authors and should not be con-
strued to represent the US Food and Drug 
Administration’s views or policies. No official 
support or endorsement by the FDA is intended 
or should be inferred. The mention of commercial 
products, their sources, or their use in 
connection with material reported herein is not 
to be construed as either an actual or implied 
endorsement of such products by the FDA.
© 2019 The Authors Clinical Pharmacology 
& Therapeutics © 2019 American Society for 
Clinical Pharmacology and Therapeutics
 1. International Transporter Consortium 
et al. Membrane transporters in drug 
development. Nat. Rev. Drug Discov. 9, 
215–236 (2010).
 2. Giacomini, K.M., Galetin, A. & Huang, 
S.M. The International Transporter 
Consortium: summarizing advances in 
the role of transporters in drug devel-
opment. Clin. Pharmacol. Ther. 104, 
766–771 (2018).
 3. Giacomini, K.M. & Huang, S.M. 
Transporters in drug development and 
clinical pharmacology. Clin. Pharmacol. 
Ther. 94, 3–9 (2013).
 4. Wang, L. et al. Interspecies variability in 
expression of hepatobiliary transporters 
across human, dog, monkey, and rat 
as determined by quantitative proteom-
ics. Drug Metab. Dispos. 43, 367–374 
(2015).
 5. Wang, L. et al. Transporter expression 
in liver tissue from subjects with alco-
holic or hepatitis C cirrhosis quantified 
by targeted quantitative proteomics. 
Drug Metab. Dispos. 44, 1752–1758 
(2016).
 6. Prasad, B. et al. Ontogeny of hepatic 
drug transporters as quantified by 
LC-MS/MS proteomics. Clin. Pharmacol. 
Ther. 100, 362–370 (2016).
 7. Ishida, K., Ullah, M., Tóth, B., Juhasz, V. 
& Unadkat, J.D. Successful prediction 
of in vivo hepatobiliary clearances and 
hepatic concentrations of rosuvastatin 
using sandwich-cultured rat hepatocytes, 
transporter-expressing cell lines, and 
quantitative proteomics. Drug Metab. 
Dispos. 46, 66–74 (2018).
 8. Yoshikado, T. et al. PBPK modeling of 
coproporphyrin I as an endogenous 
biomarker for drug interactions involving 
inhibition of hepatic OATP1B1 and 
OATP1B3. CPT Pharmacometrics Syst. 
Pharmacol. 7, 739–747 (2018).
 9. Relling, M.V. et al. New pharmacog-
enomics research network: an open 
community catalyzing research and 
translation in precision medicine. 
Clin. Pharmacol. Ther. 102, 897–902 
(2017).
 10. Zhou, K. et al. Variation in the glucose 
transporter gene SLC2A2 is associated 
with glycemic response to metformin. 
Nat. Genet. 48, 1055–1059 (2016).
